Salud financiera de hoja de balance de Ionis Pharmaceuticals
Salud financiera controles de criterios 4/6
Ionis Pharmaceuticals tiene un patrimonio de los accionistas total de $662.5M y una deuda total de $1.8B, lo que sitúa su ratio deuda-patrimonio en 275.7%. Sus activos y pasivos totales son $3.1B y $2.4B respectivamente.
Información clave
275.7%
Ratio deuda-patrimonio
US$1.83b
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$2.49b |
| Patrimonio | US$662.47m |
| Total pasivo | US$2.42b |
| Activos totales | US$3.08b |
Actualizaciones recientes sobre salud financiera
Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?
Jul 28
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 07Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Aug 03Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
May 05Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
Jan 20Recent updates
Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling
Oct 23There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding
Aug 24Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value
Aug 11Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?
Jul 28Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
May 28Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report
May 09Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S
Apr 14Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain
Feb 23Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected
Dec 28Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 07A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Nov 16Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Aug 03Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
May 05Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
Jan 20Ionis Pharmaceuticals Looks Good For The Long Term
Oct 19Ionis plans for new manufacturing site in California to support pipeline
Oct 13Ionis: 2 Drug Advancements With Potential Firsts
Aug 29Ionis Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($2.7B) de IONS superan a sus pasivos a corto plazo ($304.6M).
Pasivo a largo plazo: Los activos a corto plazo de IONS ($2.7B) superan a sus pasivos a largo plazo ($2.1B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: IONS tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de IONS ha crecido de 43.8% a 275.7% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: IONS tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.
Pronóstico de cash runway: Datos insuficientes para determinar si IONS tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.